These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24768782)

  • 1. Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.
    Tulsyan S; Agarwal G; Lal P; Mittal B
    Clin Chim Acta; 2014 Jul; 434():21-8. PubMed ID: 24768782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
    Tulsyan S; Chaturvedi P; Singh AK; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
    Gene; 2014 Jun; 543(1):69-75. PubMed ID: 24704000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
    Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
    Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.
    Agarwal G; Tulsyan S; Lal P; Mittal B
    World J Surg; 2016 Jul; 40(7):1600-10. PubMed ID: 26506825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
    Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
    Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
    Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
    Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
    Low SK; Kiyotani K; Mushiroda T; Daigo Y; Nakamura Y; Zembutsu H
    J Hum Genet; 2009 Oct; 54(10):564-71. PubMed ID: 19696793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer].
    Tang JH; Zhao JH; Wu JZ; Lu JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):108-13. PubMed ID: 19538885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
    Afsar NA; Ufer M; Haenisch S; Remmler C; Mateen A; Usman A; Ahmed KZ; Ahmad HR; Cascorbi I
    Eur J Clin Pharmacol; 2012 Apr; 68(4):389-95. PubMed ID: 22012257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
    Seredina TA; Goreva OB; Talaban VO; Grishanova AY; Lyakhovich VV
    BMC Med Genet; 2012 Jun; 13():45. PubMed ID: 22702493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of cytochrome P450 enzymes in human nasopharyngeal carcinoma and non-cancerous nasopharynx tissue].
    Jiang JH; Jia WH; Qin HD; Liang H; Pan ZG; Zeng YX
    Ai Zheng; 2004 Jun; 23(6):672-7. PubMed ID: 15191668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.
    Shu W; Chen L; Hu X; Zhang M; Chen W; Ma L; Liu X; Huang J; Pang T; Li J; Zhang Y
    J Clin Pharmacol; 2017 Jul; 57(7):886-898. PubMed ID: 28181240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer.
    Marsh S; Somlo G; Li X; Frankel P; King CR; Shannon WD; McLeod HL; Synold TW
    Pharmacogenomics J; 2007 Oct; 7(5):362-5. PubMed ID: 17224914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis.
    Modugno F; Knoll C; Kanbour-Shakir A; Romkes M
    Breast Cancer Res Treat; 2003 Dec; 82(3):191-7. PubMed ID: 14703066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
    Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
    J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.